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over the period. However, cost of health care remains an important impediment to 
access health care particularly in rural areas.
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OBJECTIVES: There is little understanding on the true cost of operating room time in 
Canada despite the fact that surgical care is paid for by a single payer facing increas-
ing cost constraints. The objective of the review was to analyze how OR costs are 
currently conceived of in Canadian hospitals. Additionally, a micro costing approach 
was used to estimate the actual cost using a bottom-up approach. METHODS: A 
literature search was conducted to determine how Canadian hospitals perceived the 
value of one hour of operating time. Studies satisfying the defined criteria were com-
pared in terms of methodology and inclusion and exclusion of specific resources 
in their perception of their institution’s OR expenditure. All costs were adjusted 
to 2014 Canadian dollars. Additionally, we conducted an independent bottom-up 
micro-costing analysis of Canadian operating room time. Completion of the litera-
ture review prior to micro costing ensured a robust and comprehensive approach 
was used. Costs were obtained using peer-reviewed literature and from a large 
Canadian hospital network. RESULTS: Specific search and inclusion criteria resulted 
in the inclusion of 5 studies in our analysis. The cost of OR time ranged greatly 
from $621.60 to $2288.94 per hour. All studies obtained the cost of OR time using a 
top-down case-costing approach informed with data from their respective finance 
departments. Each study was conducted at a different Canadian hospital and OR 
costs were perceived in strikingly different ways. Additionally, many of the studies 
lacked sufficient methodological details providing a challenge when comparing 
approaches. The bottom-up micro case-costing approach incorporated more than 
30 individual costs and resulted in an OR hourly cost of $1200. CONCLUSIONS: In 
Canada, there is little consensus between institutions of how to capture the costs 
of OR time. A bottom-up micro costing approach allowed for a different perspective 
and a more detailed analysis.
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OBJECTIVES: In less developed nations public resources are scarce and medicines 
are often not adequate, nor accessible for much of the population. Only limited 
quantitative data are available for analysis of the pharmaceutical expenditure in 
Mongolia. METHODS: Retrospective data collection on pharmaceutic expenditure 
from government issued reports were collected and analysed for the period of six 
years starting from 2009 until 2014. RESULTS: The gross domestic product (GDP) was 
11.52 billion USD in 2013 in Mongolia and the proportion of total health expenditure 
(THE) was 566.5 billion Mongolian National Tugrug (MNT) or 301.4 million USD. For 
2014, the total pharmaceutical expenditure (TPE) was 81.3 billion MNT or 11.6% of 
the THE. The public pharmaceutical expenditure (PPE) per capita was 28727.9 MNT 
or 15.3 USD in 2013. Mongolia is a developing country and the public expenditure on 
pharmaceuticals per capita was in the mid-range of developing country expenditure. 
The funding source of pharmaceuticals in Mongolia was analysed and the external 
source played a minimal role for TPE (4.8%) whereas government sourced fund (tax) 
was the highest (80.4%). Currently, no data are available on private health funds 
in Mongolia. Previous findings reported that out-of-pocket payments for health 
service has increased from 14.5% of the THE in 1995 to 41.4% in 2010. However, 
data in regards to out-of-pocket payment for pharmaceuticals were not availa-
ble. CONCLUSIONS: This study provided country specific estimates of expenditure 
funded by public source at the national level in regards with total pharmaceutical 
expenditure and per capita. in addition, data on private funding for pharmaceuticals 
are required in order to conduct the specific policy analyses including different cost 
items, equity of access, allocative efficiency, therapeutic and operation efficiency. 
However, the results of this review can be used as a baseline for monitoring future 
trends in pharmaceutical expenditure over time in Mongolia.
PHP78
cross section AnALysis of MArginAL nHs exPenditure by engLAnd 
HeALtH AreA
Hernandez-Villafuerte K., Sussex J.
Office of Health Economics, London, UK
OBJECTIVES: The cost-effectiveness threshold applied in the process of recom-
mendation of new health technologies is a central topic of discussion in the UK. A 
key element in the discussions is the marginal effect that a change on the health 
expenditure has on mortality per health category; since this is an indication of the 
opportunity cost of adopting a new technology. The common assumption is that all 
health areas behave in roughly the same way as each other when faced with a cut 
in available funds. This suggests that the opportunity cost, and consequently the 
threshold value, is the same regardless health area. This overlooks potential dif-
ferences between health areas (e.g. the way in which health services are provided 
in different localities). If there are such differences then different health areas will 
be producing health gain in different ways, and will produce different health gains 
per pound spent. The primary aim of this study is to test the assumption that 
health areas are similar to one another in the decisions they make. METHODS: 
We applied the Cluster Analysis Methodology. We propose a division in which the 
health areas within one cluster are those that are similar to each other in terms 
of the expenditures (adjusted by costs differences and needs) allocated to each 
health categories. Four clusters partitions are estimated, each one based on a dif-
ferent year. By doing this, we are able to compare the composition of the different 
groups over time. RESULTS: The data indicates that some health areas spent dif-
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OBJECTIVES: Medication errors (ME) are defined as any preventable event that may 
cause or lead to inappropriate medication use or patient harm. ME are garnering 
national attention as evidenced by the National Action Plan for Adverse Drug Event 
Prevention to drive prevention strategies for high-risk drug classes. We sought to 
understand the economic burden of ME that lead to preventable adverse drug events 
(pADEs) in US hospitals. METHODS: From a broader literature review on inject-
able ME in Medline and Embase (2003-2014), we identified eleven articles related 
to the incidence and economic impact of pADEs arising from all ME. A supplemen-
tal PubMed search identified four additional articles dating back to 1995. All cost 
estimates were converted into 2014 dollars. RESULTS: Published estimates of ME 
cost varied based on population, setting of care, methodology and study period. 
Three studies estimated the annual cost of pADEs for the inpatient setting at the 
national level. A 1999 study estimated that annual national costs of pADEs were 
$4.8 billion, while a 2012 study showed that injectable-related pADEs alone cost 
$2.8-5.2 billion. For Medicare beneficiaries, pADEs cost $617 million annually. At the 
individual hospital level, the total annual cost of pADEs ranged from $0.9 to $5.6 
million. Costs per individual pADE differed based on severity, and ranged from $3408 
to $6931. Key cost drivers included increased length of stay, additional laboratory 
testing, routine care, surgical, and other ancillary charges. CONCLUSIONS: This 
literature review highlights the economic burden of ME in the US. Cost estimates 
varied considerably due to different definitions, study methodologies, and analytic 
scope. Given the emergence of pADE harm reduction as a national priority, there is 
a need for updated research aimed at evaluating the economic impact of medica-
tion errors using standardized definitions for types of errors, their severity and the 
ensuing financial impact.
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OBJECTIVES: To quantify the financial impact of poor blood specimen quality on 
treatment and hospital costs in a healthcare facility in China, using institution 
specific data. METHODS: The data were collected from six hospitals (beds≥ 500) in 
Beijing, Shanghai and Guangzhou by interviewing institution staff, including opera-
tional data such as total operating costs, medical treatment data such as probability 
of a low, medium or high impact of a rejection, laboratory data such as total number 
of blood tests. The patients were divided into three categories: critical inpatients, 
routine outpatients, and elective surgery inpatients, since the costs of an error vary 
greatly among the three categories. Finally, the data were entered into a model to 
calculate the possible financial impact of blood specimen rejection. RESULTS: The 
estimated average costs of a blood specimen rejection were $56, $250 for critical 
inpatient, $31 for other inpatient, and $39 for outpatient, respectively. On average, 
pre-analytical specimen error costs were $494, 422, accounting for 0.12% of total hos-
pital operational costs. The impact of errors on efficiency can be assessed by hours 
lost, there is an estimated 16,913 total patient hours was lost in one year, equaling 
to short of 4029 patients treatment. 3.62% (612) of hours lost was due to laboratory 
redraw and retest, and 96.38%(16,301) was due to patient treatment. In a healthcare 
facility, patient treatment costs represent the largest cost category at 92.18%, redraw 
costs at 3.21%, instrument downtime costs at 2.99%, lab investigation costs at 1.57%, 
and blood collection consumables at 0.05%. CONCLUSIONS: Blood specimen rejec-
tions due to the poor pre-analytical quality increase operational costs and decrease 
the efficiency of hospitals, healthcare facility should monitor pre-analytical blood 
processes and use high-quality device to decrease pre-analytical errors.
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OBJECTIVES: This analysis investigates regional variation in catastrophic health 
care spending in Pakistan. METHODS: The study draws data from three rounds 
of Pakistan Living Standards Measurement Survey (PLSM) conducted in both rural 
and urban areas of Pakistan in 2005-06, 2007-08 and 2010-11. A household is clas-
sified as incurring catastrophic health expenditure if 10% or more of its annual 
expenditure is on health care. Household economic status is measured using house-
hold annual consumption expenditures and households are categorized into quin-
tiles. RESULTS: The proportion of households incurring catastrophic health care 
expenditure has declined from 7.5% in 2005-06 to 3.2% in 2010-11. The decline has 
been slightly more in case of rural households than in urban (4.9% urban and 9.1% 
rural households in 2005-06 vs. 2.0% urban and 3.8% rural households in 2010-11 
incurred catastrophic health care spending. Of poorest households, 7.5% incurred 
catastrophic health expenditure in 2005-06, 5.4% in 2007-08 and 3.5% in 2010-11 
whereas, of richest, the proportion was 6.2%, 5.4% and 2.7% for respective periods. 
Further, significantly more households in Punjab are incurring catastrophic health 
care expenditure compared to Sindh. There is regional variation across regions 
and remarkable decline in catastrophic health care spending. South Punjab had 
the highest proportion (13.6%) while south Sindh had lowest proportion (2.4%) of 
households incurring health care expenditure in 2005-06. South Sindh still has the 
lowest proportion (0.4%) whereas, north Punjab replaces south Punjab having the 
highest proportion (5.4%) of households incurring catastrophic health expenditure 
in 2010-11. CONCLUSIONS: Pakistan has registered a decline in catastrophic health 
care spending over the period. It could be associated with a decline in morbidity 
